Zoll Zeroes In On TherOx, Acquires SSO2 Therapy
Executive Summary
Just months after receiving USA FDA approval for its SuperSaturated Oxygen (SSO2) Therapy for heart-attack treatment, Californian company TherOx has been acquired by Zoll Medical for an undisclosed sum.
You may also be interested in...
Device/Diagnostics Quarterly Dealmaking Statistics, Q2 2019
Device financing totaled $2.3bn for Q2 2019, with the debt category bringing in the most money. Merger and acquisition deals reached an aggregate $9.1bn (a 25% increase from Q1), thanks mostly to 3M’s $6.7bn takeover of Acelity and its KCI subsidiaries. Diagnostics/research financing, which totaled $2.4bn, showed a significant rise from the previous quarter, while diagnostics/research tools M&A values, at $233m, exhibited a steep decline.
FDA Approves TherOx’s SuperSaturated Oxygen Heart Attack Therapy
Clinical trials have shown that SuperSaturated Oxygen Therapy (SSO2 Therapy) reduces the size of myocardial infarcts in the regions of the heart-muscle perfused by the patient’s left anterior descending coronary artery immediately following stenting.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.